The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

"Regeneron has invested many years of effort into its design and development of EYLEA® (aflibercept) Injection 2 mg. This ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...

As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%. This legal setback for Regeneron comes amid competitive pressures in the ...

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to ...

Here's the rundown. Regeneron's issues in the past year are almost entirely related to Eylea, a medicine for wet age-related macular degeneration, which it co-markets with Bayer. The Eylea ...

Eylea’s sales in the United States declined 11% year over year to $1.2 billion, primarily due to increased competition. Please note that Regeneron co-developed Eylea with the HealthCare unit of ...